Sutures, staples, clips and other wound closure still active in development

See the updated, published 2012 Report #S190, “Surgical Sealants, Glues, Sutures, Other Wound Closure and Anti-Adhesion, Worldwide Markets, 2012-2017.”

In our analyses of the market for surgical sealant, glues, wound closure, hemostasis and ant-adhesion products (Report #S180), we highlight that a major force in the development of these new products is in manufacturers driving innovation to enable the products to displace traditional wound closure products, especially sutures, staples and clips.

Given the size of this “mechanical closure” market, at over $5 billion annually, manufacturers in this space are not idly standing by while novel wound closure technologies poach their caseload.  A healthy number of companies are actively developing and marketing novel wound closure products that still fall in this traditional category of wound closure:

Source: MedMarket Diligence, LLC; Report #S180.


Companies represented here (many involved in development of multiple wound closure product types) include: 3M, Abbott Vascular, Angiotech Pharmaceuticals, ArthroCare , B. Braun/Aesculap, BSN Medical, Cardiva Medical, Covidien, CSMG Technologies (Live Tissue Connect), Incisive Surgical, Innovasa, Johnson & Johnson (Ethicon), Kinetic Concepts, Morris Innovative, NeatStitch, Resorba, St. Jude Medical, Synovis Life Technologies, Teleflex Medical, Wound Care Technologies, and Zimmer.

This does not include the companies active in the area of medical/surgical tapes in a range of types; fabric, film, island, bandage, impregnated and others.

2 thoughts on “Sutures, staples, clips and other wound closure still active in development”

  1. I’m responding to this blog I’ve just read regarding tissue bonding and I’m interested in the viability of Live Tissue Connect CSMG as a company. does it really exist or is it an elaborate scam to lure in investors? I ask because I’ve invested heavily in the company through empire financial group, going back to 2007 prior to the IPO of the company, promising massive returns. But it now all feels like it is just a scam and there is nothing to be gained but a massive loss. There seems to be a few law suits against Empire Financial for this including myself. I’m wondering is LTC for real. Please pass on any information you mY have on this matter.
    Kind regards

  2. The technology that has been under development by Live Tissue Connect (now supposedly part of CSMG or “Consortium Service Management Group”) has received patents and has received CE Mark and FDA approval. For this reason, we have covered Live Tissue Connect in our current and prior editions of our reports on surgical sealants, wound closure and related technologies. However, the lack of current information on Live Tissue Connect and its products and the similar lack of information on CSMG (including that their website, is no longer active) certainly suggests that, however credible or viable the technology may be (or may have been), the company has not been able to leverage it, and the company itself has such a suspiciously low visibility that I would question CSMG’s value as an ongoing concern. Please note that I have no vested interest in CSMG or its competitors and that I am neither benefitted nor disadvantaged by providing this information. As our business is focused on assessing market impacts of current and future technologies in medtech, our position on this is that that we see no particular “upside” to this technology for this reason, but we are not in the business of valuing companies. Therefore, my recommendation to you is that you aggressively investigate CSMG independently to reach any conclusion regarding investment in the company.

Leave a Reply